Mohammed S I, Knapp D W, Bostwick D G, Foster R S, Khan K N, Masferrer J L, Woerner B M, Snyder P W, Koki A T
Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana 47907, USA.
Cancer Res. 1999 Nov 15;59(22):5647-50.
Cyclooxygenase (COX)-inhibiting drugs have antitumor activity in canine and rodent models of urinary bladder cancer. Two isoenzymes of COX have been identified, COX-1 and COX-2. The purpose of this study was to characterize COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by immunohistochemistry and Western blot analysis. COX-2 was not expressed in normal urinary bladder samples but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and in 6 of 8 (75%) cases of carcinoma in situ. These results indicate that COX-2 may play a role in bladder cancer in humans and support further study of COX-2 inhibitors as potential antitumor agents in human bladder cancer.
环氧化酶(COX)抑制药物在犬类和啮齿类膀胱癌模型中具有抗肿瘤活性。已鉴定出COX的两种同工酶,即COX-1和COX-2。本研究的目的是通过免疫组织化学和蛋白质印迹分析来描述COX-1和COX-2在人浸润性膀胱移行细胞癌中的表达情况。COX-2在正常膀胱样本中未表达,但在29例浸润性膀胱移行细胞癌中的25例(86%)以及8例原位癌中的6例(75%)中被检测到。这些结果表明COX-2可能在人类膀胱癌中发挥作用,并支持进一步研究COX-2抑制剂作为人类膀胱癌潜在抗肿瘤药物的可能性。